DYN
Dyne Therapeutics, Inc.
Stock
$15.20−0.62 (−3.92%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $898M | $1.1B | $642M | $123M | $256M | $377M | $345M | $15M |
| Current assets | $938M | $1.1B | $659M | $129M | $266M | $382M | $349M | $15M |
| Total assets | $994M | $1.2B | $691M | $165M | $306M | $426M | $353M | $16M |
| Current liabilities | $78M | $51M | $42M | $51M | $28M | $29M | $11M | $2.4M |
| Long-term debt | $199M | $149M | $0 | — | — | — | — | — |
| Total liabilities | $292M | $215M | $61M | $74M | $54M | $57M | $11M | $2.4M |
| Shareholders' equity | $702M | $972M | $630M | $91M | $252M | $368M | $342M | $14M |
| Shares outstanding | 186.7M | 165.0M | 113.1M | 82.0M | 56.3M | 51.6M | 51.5M | — |
| Current ratio | 12.02 | 22.25 | 15.60 | 2.53 | 9.46 | 13.31 | 31.83 | 6.26 |